KRYS vs. NVO

In the year-to-date period, KRYS achieves a 26.26% return, which is significantly higher than NVO's 3.55% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current KRYS Sharpe Ratio is 0.62, which is higher than the NVO Sharpe Ratio of 0.27. The chart below compares the historical Sharpe Ratios of KRYS and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

KRYS has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 1.36%.

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum NVO drawdown of -71.30%. Use the drawdown chart below to compare losses from any high point for KRYS and NVO. For additional features, visit the drawdowns tool.

Krystal Biotech, Inc. (KRYS) has a higher volatility of 15.70% compared to Novo Nordisk A/S (NVO) at 7.72%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.